Erika Krasnickas Keeton

Zipalertinib in Patients With Epidermal Growth Factor Receptor Exon 20 Insertion-Positive Non–Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy With or Without Amivantamab

Zofia Piotrowska, Antonio Passaro, Danny Nguyen, Gerrina Ruiter et autres

us, it, hk, kr, nl, es, sg, tw, jp (code pays fourni par la source)

1254MO Safety and anti-tumour activity of zipalertinib in NSCLC patients (pts) with EGFR exon 20 insertion (ex20ins) mutations who received prior amivantamab

Angelina Passaro, H.A. Yu, D. Nguyen, Victor Lee et autres

it, us, hk, sg, kr, jp, es, nl (code pays fourni par la source)

UP-NEXT (GOG-3049/ENGOT-Ov71-NSGO-CTU): A study of upitifamab rilsodotin (UpRi), a NaPi2b-directed antibody drug conjugate (ADC), in platinum-sensitive recurrent ovarian cancer.

Debra L. Richardson, Philipp Harter, David M. O’Malley, Antonio González-Martı́n et autres

us, de, es, dk (code pays fourni par la source)

Data from Positive Cross-Regulatory Loop Ties GATA-3 to Estrogen Receptor α Expression in Breast Cancer

Jérôme Eeckhoute, Erika Krasnickas Keeton, Mathieu Lupien, Susan A. Krum et autres

Supplementary Figure 1-7, Table 1 from Positive Cross-Regulatory Loop Ties GATA-3 to Estrogen Receptor α Expression in Breast Cancer

Jérôme Eeckhoute, Erika Krasnickas Keeton, Mathieu Lupien, Susan A. Krum et autres

Data from Positive Cross-Regulatory Loop Ties GATA-3 to Estrogen Receptor α Expression in Breast Cancer

Jérôme Eeckhoute, Erika Krasnickas Keeton, Mathieu Lupien, Susan A. Krum et autres

Supplementary Figure 1-7, Table 1 from Positive Cross-Regulatory Loop Ties GATA-3 to Estrogen Receptor α Expression in Breast Cancer

Jérôme Eeckhoute, Erika Krasnickas Keeton, Mathieu Lupien, Susan A. Krum et autres

TP024/#446 Upgrade: phase 1 combination trial of the NAPI2B-directed antibody drug conjugate (ADC) upifitamab rilsodotin (UPRI; XMT-1536) in patients with ovarian cancer

John L. Hays, Theresa L. Werner, Nehal J. Lakhani, Jeffrey Edenfield et autres

us (code pays fourni par la source)

32 UPGRADE: phase 1 combination trial of the NaPi2b-directed antibody drug conjugate (ADC) upifitamab rilsodotin (UpRi; XMT-1536) in patients with ovarian cancer

Theresa L. Werner, Nehal J. Lakhani, William J. Edenfield, John L. Hays et autres

us, in (code pays fourni par la source)

Upgrade: Phase 1 combination trial of the NaPi2b-directed dolaflexin antibody drug conjugate (ADC) upifitamab rilsodotin (UpRi; XMT-1536) in patients with ovarian cancer (588)

Nehal J. Lakhani, Timothy F. Burns, Minal Barve, Jeffery Edenfield et autres

us, gb (code pays fourni par la source)

OVARIO, A Phase 2 Study of Niraparib + Bevacizumab in Advanced Ovarian Cancer Following Front-Line Platinum-Based Chemotherapy with Bevacizumab: Updated Analysis (039)

Melissa M. Hardesty, Thomas C. Krivak, Gail S. Wright, Erika Hamilton et autres

us (code pays fourni par la source)

OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab

Melissa M. Hardesty, Thomas C. Krivak, Gail S. Wright, Erika Hamilton et autres

us (code pays fourni par la source)